Table 2 The levels of 14 markers in nasopharyngeal carcinoma (NPC) patients and control subjects
Marker | Case–control study | Nested case–control study | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NPC patients (pg/mL) | Controls (pg/mL) | P | NPC patients (pg/mL) | Controls (pg/mL) | P | |||||||||
Median | P25 | P75 | Median | P25 | P75 | Median | P25 | P75 | Median | P25 | P75 | |||
EGF | 209.3 | 125.8 | 327.1 | 392.5 | 238.9 | 594.4 | < 0.001 | 442.3 | 274.5 | 583.5 | 477.0 | 333.4 | 629.0 | 0.26 |
Eotaxin | 126.6 | 95.4 | 174.4 | 143.6 | 106.2 | 186.9 | 0.098 | 140.0 | 96.1 | 195.4 | 139.1 | 96.0 | 212.0 | 0.86 |
GCSF | 6.5 | 1.6 | 15.6 | 15.6 | 4.3 | 50.9 | < 0.001 | 22.8 | 7.6 | 40.6 | 18.6 | 5.8 | 31.2 | 0.13 |
Fractalkine | 11.4 | 11.4 | 11.4 | 59.2 | 11.4 | 211.2 | < 0.001 | 92.9 | 11.4 | 547.2 | 92.9 | 11.4 | 380.4 | 0.76 |
IFN-γ | 6.0 | 1.6 | 25.5 | 10.0 | 3.6 | 24.5 | 0.079 | 5.8 | 1.6 | 11.6 | 4.9 | 1.6 | 11.7 | 0.87 |
GRO | 940.6 | 731.4 | 1272.0 | 1406.0 | 964.6 | 2309.5 | < 0.001 | 1926.0 | 1346.5 | 4808.5 | 1615.5 | 1209.5 | 2652.5 | 0.13 |
MDC | 861.3 | 669.8 | 1122.0 | 894.4 | 590.7 | 1179.0 | 0.89 | 883.3 | 625.1 | 1248.5 | 814.0 | 628.0 | 1122.0 | 0.55 |
IL-1α | 4.7 | 4.7 | 4.7 | 4.7 | 4.7 | 68.8 | < 0.001 | 4.7 | 4.7 | 24.4 | 4.7 | 4.7 | 98.0 | 0.08 |
IL-7 | 1.6 | 1.6 | 7.3 | 3.2 | 1.6 | 11.9 | 0.11 | 3.3 | 1.6 | 5.3 | 1.6 | 1.6 | 3.7 | 0.035 |
IL-8 | 20.4 | 7.8 | 39.8 | 16.4 | 7.5 | 34.0 | 0.48 | 58.8 | 7.3 | 269.6 | 108.2 | 13.3 | 380.4 | 0.106 |
MCP-1 | 465.2 | 348.3 | 598.1 | 400.0 | 232.9 | 568.8 | 0.004 | 617.3 | 400.0 | 789.0 | 598.1 | 450.8 | 788.8 | 0.38 |
MIP-1α | 1.6 | 1.6 | 66.5 | 29.0 | 1.6 | 95.4 | 0.023 | 25.9 | 1.6 | 57.0 | 32.6 | 4.3 | 114.5 | 0.105 |
MIP-1β | 51.5 | 25.8 | 82.6 | 62.6 | 32.0 | 102.2 | 0.036 | 69.8 | 31.2 | 116.7 | 88.5 | 43.8 | 157.8 | 0.045 |
VEGF | 297.7 | 129.0 | 594.4 | 279.6 | 129.0 | 459.3 | 0.46 | 218.8 | 79.0 | 357.2 | 188.2 | 88.5 | 364.1 | 0.73 |